Gleevec (Imatinib) - Revision history

Lazy at 08:22, 18 January 2025

2025-01-18T08:22:57Z

← Older revision		Revision as of 01:22, 18 January 2025
Line 41:		Line 41:
	tumors (in contrast to de novo glioblastomas that occur without such evolution). For this		tumors (in contrast to de novo glioblastomas that occur without such evolution). For this
	restricted patient population, the PFS-6 value was 53%.		restricted patient population, the PFS-6 value was 53%.
	}}		\|overview=Gleevec (Imatinib) is an FDA-approved drug primarily used for chronic myelogenous leukemia, with investigational use in gliomas targeting overexpression of platelet-derived growth factor receptor (PDGFR). While it has shown some promise in inhibiting glioma growth, especially in patients with PDGFR overexpression, its effectiveness is limited by challenges such as crossing the blood-brain barrier and varying resistance mechanisms.}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:35:28Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:35, 12 November 2024
Line 9:		Line 9:
	\|usefulness_rating=3		\|usefulness_rating=3
	\|notes=Gleevec, known for its role in leukemia treatment, has shown potential in inhibiting glioma growth due to its targeting of PDGF. Its effectiveness in brain tumors has been limited, possibly due to issues crossing the blood-brain barrier and various resistance mechanisms. Its use has been explored in patients with recurrent tumors and PDGFR overexpression, showing some promise in early research.		\|notes=Gleevec, known for its role in leukemia treatment, has shown potential in inhibiting glioma growth due to its targeting of PDGF. Its effectiveness in brain tumors has been limited, possibly due to issues crossing the blood-brain barrier and various resistance mechanisms. Its use has been explored in patients with recurrent tumors and PDGFR overexpression, showing some promise in early research.
	\|~~category~~=Other Chemotherapy and Cancer Drugs		\|treatment_category=Other Chemotherapy and Cancer Drugs
	\|links=		\|links=
	\|toxicity_level=3		\|toxicity_level=3

Lazy at 04:18, 28 March 2024

2024-03-28T04:18:59Z

@@ Line 13: / Line 13: @@
 |toxicity_level=3
 |toxicity_explanation=Gleevec (Imatinib) is at a moderate toxicity level. This is because while it does have side effects such as fluid retention, nausea, muscle cramps, rashes, and fatigue, these are common to most treatments and they vary from patient to patient. Also, it has not been specifically approved for glioma treatment, indicating that it might have unexpected results, slightly increasing the risk factor. However, it has shown some potential benefits in early research, hence the moderate, not high, toxicity rating.
 }}

Lazy at 16:56, 27 March 2024

2024-03-27T16:56:11Z

← Older revision		Revision as of 09:56, 27 March 2024
Line 11:		Line 11:
	\|category=Other Chemotherapy and Cancer Drugs		\|category=Other Chemotherapy and Cancer Drugs
	\|links=		\|links=
			\|toxicity_level=3
			\|toxicity_explanation=Gleevec (Imatinib) is at a moderate toxicity level. This is because while it does have side effects such as fluid retention, nausea, muscle cramps, rashes, and fatigue, these are common to most treatments and they vary from patient to patient. Also, it has not been specifically approved for glioma treatment, indicating that it might have unexpected results, slightly increasing the risk factor. However, it has shown some potential benefits in early research, hence the moderate, not high, toxicity rating.
	}}		}}

Lazy at 03:58, 26 March 2024

2024-03-26T03:58:36Z

← Older revision		Revision as of 20:58, 25 March 2024
Line 7:		Line 7:
	\|OS_with=Not applicable; studies focusing on PFS-6 as a primary endpoint		\|OS_with=Not applicable; studies focusing on PFS-6 as a primary endpoint
	\|PFS_with=PFS-6 value was 53% in a restricted patient population with overexpression of PDGFR		\|PFS_with=PFS-6 value was 53% in a restricted patient population with overexpression of PDGFR
	\|usefulness_rating=~~Investigational (Specific usefulness rating not provided due to varying outcomes and limited glioma-focused trials)~~		\|usefulness_rating=3
	\|notes=Gleevec, known for its role in leukemia treatment, has shown potential in inhibiting glioma growth due to its targeting of PDGF. Its effectiveness in brain tumors has been limited, possibly due to issues crossing the blood-brain barrier and various resistance mechanisms. Its use has been explored in patients with recurrent tumors and PDGFR overexpression, showing some promise in early research.		\|notes=Gleevec, known for its role in leukemia treatment, has shown potential in inhibiting glioma growth due to its targeting of PDGF. Its effectiveness in brain tumors has been limited, possibly due to issues crossing the blood-brain barrier and various resistance mechanisms. Its use has been explored in patients with recurrent tumors and PDGFR overexpression, showing some promise in early research.
	\|category=Other Chemotherapy and Cancer Drugs		\|category=Other Chemotherapy and Cancer Drugs
	\|links=		\|links=
	}}		}}

Lazy: Created page with "{{TreatmentInfo |drug_name=Gleevec (Imatinib) |FDA_approval=Yes (for chronic myelogenous leukemia and other cancers, not specifically approved for gliomas) |used_for=Investigational use in gliomas, specifically targeting overexpression of platelet-derived growth factor receptor (PDGFR) |clinical_trial_phase=Exploratory/Investigational (Specific phase for gliomas not provided) |common_side_effects=Varies; for leukemia treatment includes fluid retention, nausea, muscle cra..."

2024-03-24T13:23:25Z

Created page with "{{TreatmentInfo |drug_name=Gleevec (Imatinib) |FDA_approval=Yes (for chronic myelogenous leukemia and other cancers, not specifically approved for gliomas) |used_for=Investigational use in gliomas, specifically targeting overexpression of platelet-derived growth factor receptor (PDGFR) |clinical_trial_phase=Exploratory/Investigational (Specific phase for gliomas not provided) |common_side_effects=Varies; for leukemia treatment includes fluid retention, nausea, muscle cra..."

New page

{{TreatmentInfo
|drug_name=Gleevec (Imatinib)
|FDA_approval=Yes (for chronic myelogenous leukemia and other cancers, not specifically approved for gliomas)
|used_for=Investigational use in gliomas, specifically targeting overexpression of platelet-derived growth factor receptor (PDGFR)
|clinical_trial_phase=Exploratory/Investigational (Specific phase for gliomas not provided)
|common_side_effects=Varies; for leukemia treatment includes fluid retention, nausea, muscle cramps, rashes, and fatigue. Brain tumor studies may have different profiles due to combination treatments and patient population.
|OS_with=Not applicable; studies focusing on PFS-6 as a primary endpoint
|PFS_with=PFS-6 value was 53% in a restricted patient population with overexpression of PDGFR
|usefulness_rating=Investigational (Specific usefulness rating not provided due to varying outcomes and limited glioma-focused trials)
|notes=Gleevec, known for its role in leukemia treatment, has shown potential in inhibiting glioma growth due to its targeting of PDGF. Its effectiveness in brain tumors has been limited, possibly due to issues crossing the blood-brain barrier and various resistance mechanisms. Its use has been explored in patients with recurrent tumors and PDGFR overexpression, showing some promise in early research.
|category=Other Chemotherapy and Cancer Drugs
|links=
}}